Categories

REBLOZYL Approved by the FDA

The US Food and Drug Administration recently approved REBLOZYL® (luspatercept-aamt), the first and only erythroid maturation agent (EMA) indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of […]

Read More No Comments

FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma

Released:  November 14, 2019 The U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma usually responds well to initial treatment, but eventually returns or stops responding, and the cancer cells continue […]

Read More No Comments

Merck announces new pack for KEYTRUDA®

Merck is pleased to announce the availability of a new pack for KEYTRUDA® (pembrolizumab)Injection 100 mg/4 mL (25 mg/mL) (“KEYTRUDA”).The new pack contains two 100mg/4 mL single-dose vials in a single carton. The price per vial of KEYTRUDA is not affected by the introduction of this new pack. The National Drug Code (NDC) for this […]

Read More No Comments

US Food and Drug Administration approves INREBIC® for Treatment

INREBIC® (fedratinib) capsules, a product from Celgene, is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INDICATION INREBIC® (fedratinib) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). IMPORTANT SAFETY […]

Read More No Comments

KEYTRUDA approved by FDA for first-line treatment of patients with HNSCC

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

Read More No Comments

Pfizer announces a first-line combination Rx for advanced RCC.

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

Read More No Comments

CMS finalizes rule which forces drug manufacturers to provide the list price for their products in direct-to-consumer ads.

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

Read More No Comments

Merck announces new FDA approval for KEYTRUDA

Merck announces new FDA approval for KEYTRUDA Merck is pleased to announce that KEYTRUDA, in combination with axitinib, has been approved by the FDA for the first-line treatment of patients with advanced renal cell carcinoma (RCC). PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients FDA=Food and Drug Administration; PD-L1=programmed […]

Read More No Comments

AstraZeneca announces new CMS J-code assigned for IMFINZI®

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS). Effective for dates of services on or after January 1, 2019, J-Code J9173 can be used to identify IMFINZI® (durvalumab) when billing across settings of care as noted in the […]

Read More No Comments

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients With Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma (MCC)

Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and […]

Read More No Comments